Can a Leading Laboratory Unlock the Cause of Gastrointestinal Disease?
Faranak Fattahi’s lab is a national leader in growing stem cells to model peripheral nerves, focusing on gastrointestinal diseases.
University of California San Francisco
Give to UCSFFaranak Fattahi’s lab is a national leader in growing stem cells to model peripheral nerves, focusing on gastrointestinal diseases.
Increasing a newborn’s blood pressure after heart surgery may reduce brain injuries and increase survival for infants.
Sleep medications may increase risk of dementia for white people, though the type and amount of medication may also explain the higher probability.
Could psychedelics become mainstream medicines?
Resecting brain tumors called gliomas as much as possible soon after diagnosis offers a distinct survival advantage when looking at the disease trajectory 10 years later, find UCSF researchers.
UCSF experts discuss the current state of Alzheimer’s treatments and future therapies that may slow progression of the disease.
Through decades of biobanking at UCSF, researchers were able to comprehensively map intra-cellular signaling in the cells of recurrent glioblastoma, identifying novel cell-extrinsic therapeutic targets.
While we sleep, our brains process our daily actions to create motor memory, which makes physical acts such as throwing a basketball subconscious.
UCSF Experts Present Research at the Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference in San Francisco.
Risk of death or hospitalization from COVID-19 were found to be greater for patients with PTSD.
The brains of people with Down syndrome develop the same neurodegenerative tangles and plaques associated with Alzheimer’s disease and frequently demonstrate signs of the neurodegenerative disorder in their forties or fifties. A new study shows that these tangles and plaques are driven by the same amyloid beta (Aß) and tau prions as Alzheimer’s disease.
Brain implants for speech, neurological effects of COVID-19, and motor recovery after stroke are among the topics that researchers from UCSF will be presenting at this year’s annual meeting of the Society for Neuroscience.
A $147 million grant will expand diversity among Alzheimer’s disease research participants, and involve partners from UCSF, the San Francisco VA Medical Center, and the Northern California Institute for Research and Education.